MiR-203 Determines Poor Outcome and Suppresses Tumor Growth by Targeting TBK1 in Osteosarcoma

Liu, Shiping; Peng, Feng

doi:10.1159/000438556

Cited by 17 publications

(14 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Evidence shows that miR-203 acts an important role in the regulation of tumor proliferation, migration and invasion. Some studies indicate that miR-203 overexpression suppresses cell growth and metastasis via targeting different genes in different tumor tissues, such as targeting TBK1 in Osteosarcoma [ 28 ], ADAM9 and long non-coding RNA HULC in hepatocellular carcinoma [ 29 ], Rap1A in prostate cancer [ 30 ], Ran and miR-21 in esophageal cancer [ 31 ]. However, few studies show that miR-203 may function as the carcinogenic factor via enhancing cell proliferation, migration and invasion by degrading SIK1 in pancreatic cancer [ 32 ].…”

Section: Discussionmentioning

confidence: 99%

MicroRNA-203 suppresses gastric cancer growth by targeting PIBF1/Akt signaling

Chu

Wang

Zhang

et al. 2016

J Exp Clin Cancer Res

View full text Add to dashboard Cite

BackgroundMicroRNAs (miRNAs) have been proved involved in many tumorigenic behaviors including tumor growth. But, the clinical significance and functions of miRNA-203 in gastric cancer (GC) remain elusive.ResultsDecreased expression of miRNA-203 was correlated with tumor size, poor prognosis and recurrence in GC patients. Overexpression of miR-203 or knockdown of its target progesterone immunomodulatory binding factor 1 (PIBF1) inhibited GC growth in vitro and in vivo, while miR-203 knockdown promoted GC proliferation. In addition, PIBF1 overexpression attenuated the inhibitory effects of miR-203 on GC growth and enhanced that effect on p-Akt expression.ConclusionsMiR-203 as a tumor biomarker suppresses GC growth through targeting the PIBF1/Akt signaling, suggesting that it may have the important therapeutic potential for the treatment of GC.Electronic supplementary materialThe online version of this article (doi:10.1186/s13046-016-0323-1) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

MicroRNA-203 suppresses gastric cancer growth by targeting PIBF1/Akt signaling

Chu

Wang

Zhang

et al. 2016

J Exp Clin Cancer Res

View full text Add to dashboard Cite

show abstract

“…MiR-203 can strongly decrease the fraction of side population cells and colony formation by targeting Bmi-1 in esophageal cancer and leukemia stem cell [5, 52]. In osteosarcoma, inhibition of miR-203 stimulated cell growth by targeting TBK1 and RAB22A [53, 54]. Therefore, miR-203 is involved in tumor cell differentiation, proliferation and metastasis, and is thought to be a tumor suppressor.…”

Section: Discussionmentioning

confidence: 99%

Evaluating the Prognostic Value of microRNA-203 in Solid Tumors Based on a Meta-Analysis and the Cancer Genome Atlas (TCGA) Datasets

Shao

Ning

et al. 2017

Cell Physiol Biochem

View full text Add to dashboard Cite

Background: It has been reported that miR-203 expression was aberrant in various types of cancers, and it could be used as a prognostic biomarker. Therefore, in this study, we aimed to evaluate the prognostic value of miR-203 expression in solid tumors by using meta-analysis and The Cancer Genome Atlas (TCGA) datasets. Methods: By doing a literature research in PubMed, Embase and the Cochrane Library (last update by December 2016), we were able to identify the studies assessing the prognostic role of miR-203 in various tumors. We then used TCGA datasets to validate the results of meta-analysis. Results:33 studies from 26 articles were qualified and enrolled in this meta-analysis. Pooled analyses showed that higher expression of miR-203 in tissues couldn’t predict poor overall survival (OS) and progression-free survival (PFS) in solid tumors. However, the results of subgroup analyses revealed that the upregulation of tissue miR-203 expression was associated with poor OS in colorectal cancer (hazard ratio (HR)=1.81, 95% confidence intervals (CI) 1.31-2.49; P<0.001), pancreatic cancer (HR=1.19, 95% CI 1.09-1.31; P<0.001) and ovarian cancer (HR=1.85, 95% CI 1.45-2.37; P<0.001); but it had opposite association in liver cancer (HR=0.52, 95% CI 0.28-0.97; P=0.040) and esophageal cancer (HR=0.41, 95% CI 0.25-0.66; P<0.001). Based on TCGA datasets, we found the same results for pancreatic cancer and esophageal cancer, but not for colorectal cancer and liver cancer. Moreover, patients with high circulating miR-203 in blood had significantly poor OS and PFS in colorectal cancer and breast cancer. Conclusion: Our study showed that the prognostic values of tissue miR-203 varied in different tumor types. In addition, the upregulation of circulating miR-203 in blood was associated with poor prognosis in colorectal cancer and breast cancer.

show abstract

“…MiR-203 is located in a frequently lost chromosomal region in T cell malignancies [ 17 ], and its expression is downregulated in tumors [ 9 – 12 , 18 , 19 ]. Previous study has demonstrated miR-203 was a putative tumor suppressor gene in several tumors.…”

Section: Discussionmentioning

confidence: 99%

“…Recently, Liu et al reported miR-203 was down regulated in osteosarcoma tissues and cell lines. Decreased miR-203 was associated with a poor prognosis in osteosarcoma patients [ 18 ]. Inhibition of miR-203 stimulated osteosarcoma cell growth by targeting TBK1, proliferation and RAB22A [ 18 , 27 , 28 ].…”

Section: Discussionmentioning

confidence: 99%

Development and validation of nomogram based on miR-203 and clinicopathological characteristics predicting survival after neoadjuvant chemotherapy and surgery for patients with non-metastatic osteosarcoma

et al. 2017

View full text Add to dashboard Cite

BackgroundRecently, nomograms have been used as models for risk prediction in malignant tumor because they can predict the outcome of interest for a certain individual based on many variables. This study aimed to establish an effective prognostic nomogram for osteosarcoma based on the clinicopathological factors and microRNA-203.ResultsThe results showed that miR-203 expression was significantly lower in osteosarcoma tissues compared with the corresponding adjacent tissues (P < 0.001). Patients with low miR-203 expression had poor overall survival (OS) in osteosarcoma. The histological type, tumor size, AJCC stage and miR-203 expression were integrated in the nomogram. The nomogram showed significantly better prediction of OS than for patients with non-metastatic osteosarcoma. The ROC curve also showed higher specificity and sensitivity for predicting 3- and 5-year osteosarcoma patients’ survival compared with AJCC stage. The decision curve analysis also indicated more potential of clinical application of the nomogram compared with AJCC staging system. Moreover, our findings were supported by the validation cohort.Materials and MethodsWe retrospectively investigated 301 patients with non-metastatic osteosarcoma. Data from primary cohort (n = 198) were used to develop multivariate nomograms. This nomogram was internally validated for discrimination and calibration with bootstrap samples and was externally validated with an independent patient cohort (n = 103).ConclusionsOur proposed nomogram showed more accurate prognostic prediction for patients with non-metastatic osteosarcoma.

show abstract

MiR-203 Determines Poor Outcome and Suppresses Tumor Growth by Targeting TBK1 in Osteosarcoma

Cited by 17 publications

References 23 publications

MicroRNA-203 suppresses gastric cancer growth by targeting PIBF1/Akt signaling

MicroRNA-203 suppresses gastric cancer growth by targeting PIBF1/Akt signaling

Evaluating the Prognostic Value of microRNA-203 in Solid Tumors Based on a Meta-Analysis and the Cancer Genome Atlas (TCGA) Datasets

Development and validation of nomogram based on miR-203 and clinicopathological characteristics predicting survival after neoadjuvant chemotherapy and surgery for patients with non-metastatic osteosarcoma

Contact Info

Product

Resources

About